drugset
drugset / Trial / NCT03374241

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

NCT03374241 ↗

Phase 1 Completed 41 enrolled Hanmi Pharmaceutical Company Limited
RandomizedSequentialTriple-blindTreatment

Summary

Single ascending dose of HM15211 in healthy obese subjects.

Timeline

Start
2018-04-04
Primary completion
2018-09-14
Completion
2018-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Efocipegtrutide Protein / enzyme biologic — Subcutaneous

Indications

obesity disorder